BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 14518305)

  • 21. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 in epidermoid cancer of the esophagus.
    Tanaka M; Nonogaki S; Alberti VN; Forones NM
    Hepatogastroenterology; 1999; 46(27):1765-8. PubMed ID: 10430340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 Mutations in carcinoma of the esophagus and gastroesophageal junction.
    Sengpiel C; König IR; Rades D; Noack F; Duchrow M; Schild SE; Ludwig D; Homann N
    Cancer Invest; 2009 Jan; 27(1):96-104. PubMed ID: 19160092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).
    Cronin J; McAdam E; Danikas A; Tselepis C; Griffiths P; Baxter J; Thomas L; Manson J; Jenkins G
    Am J Gastroenterol; 2011 Jan; 106(1):46-56. PubMed ID: 21157443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
    Vaninetti NM; Geldenhuys L; Porter GA; Risch H; Hainaut P; Guernsey DL; Casson AG
    Mol Carcinog; 2008 Apr; 47(4):275-85. PubMed ID: 17849424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Profile of p53 mutations and abnormal expression of P53 protein in 2 forms of esophageal cancer].
    Muzeau F; Fléjou JF; Potet F; Belghiti J; Thomas G; Hamelin R
    Gastroenterol Clin Biol; 1996; 20(5):430-7. PubMed ID: 8761140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of p53 in Barrett's oesophagus.
    Krishnadath KK; van Blankenstein M; Tilanus HW
    Eur J Gastroenterol Hepatol; 1995 Jan; 7(1):81-4. PubMed ID: 7866817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased expression of the cyclin D1 gene in Barrett's esophagus.
    Arber N; Lightdale C; Rotterdam H; Han KH; Sgambato A; Yap E; Ahsan H; Finegold J; Stevens PD; Green PH; Hibshoosh H; Neugut AI; Holt PR; Weinstein IB
    Cancer Epidemiol Biomarkers Prev; 1996 Jun; 5(6):457-9. PubMed ID: 8781742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
    Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
    Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multistage carcinogenesis in Barrett's esophagus.
    Maley CC
    Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression.
    Doak SH; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
    Mutat Res; 2004 Mar; 547(1-2):133-44. PubMed ID: 15013707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus.
    Ooi A; Zen Y; Ninomiya I; Tajiri R; Suzuki S; Kobayashi H; Imoto I; Dobashi Y
    Pathol Int; 2010 Jun; 60(6):466-71. PubMed ID: 20518902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma.
    Blount PL; Ramel S; Raskind WH; Haggitt RC; Sanchez CA; Dean PJ; Rabinovitch PS; Reid BJ
    Cancer Res; 1991 Oct; 51(20):5482-6. PubMed ID: 1680552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.
    Casson AG; Evans SC; Gillis A; Porter GA; Veugelers P; Darnton SJ; Guernsey DL; Hainaut P
    J Thorac Cardiovasc Surg; 2003 May; 125(5):1121-31. PubMed ID: 12771886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
    Chung SM; Kao J; Hyjek E; Chen YT
    Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Overexpression of protein p53 and Barrett esophagus. A frequent and early event in the course of carcinogenesis].
    Fléjou JF; Volant A; Diebold MD; Sagan C; Vissuzaine C; Croué A; Robaszkiewicz M; Potet F
    Gastroenterol Clin Biol; 1995 May; 19(5):475-81. PubMed ID: 7589998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.